title: Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC.
abstract: The anti-tumor effect of monocyte-derived DC (MoDC) vaccine was studied in lung cancer model with feasible but weak Ag-specific immune response and incomplete blocking of tumor growth. To overcome this limitation, the hematopoietic stem cell-derived DC (SDC) was cultured and the anti-tumor effect of MoDC & SDC was compared in mouse lung cancer minimal residual model (MRD). Therapeutic DCs were cultured from either CD34(+) hematopoietic stem cells with GM-CSF, SCF and IL-4 for 14 days (SDC) or monocytes with GM-CSF and IL-4 for 7 days (MoDC). DCs were injected twice by one week interval into the peritoneum of mice that are inoculated with Lewis Lung Carcinoma cells (LLC) one day before the DC injection. Anti-tumor responses and the immune modulation were observed 3 weeks after the final DC injection. CD11c expression, IL-12 and TGF-β secretion were higher in SDC but CCR7 expression, IFN-γ and IL-10 secretion were higher in MoDC. The proportion of CD11c(+)CD8a(+) cells was similar in both DC cultures. Although both DC reduced the tumor burden, histological anti-tumor effect and the frequencies of IFN-γ secreting CD8(+) T cells were higher in SDC treated group than in MoDC. Conclusively, although both MoDC and SDC can induce the anti-tumor immunity, SDC may be better module as anti-tumor vaccine than MoDC in mouse lung cancer.
authors: Office of Biomedical Professors, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.
authors: Soyoung
authors: S
authors: Baek
authors: Seog Jae
authors: SJ
authors: Lee
authors: Myoung Joo
authors: MJ
authors: Kim
authors: Hyunah
authors: H
authors: Lee
keywords: Anti-tumor immunity; Dendritic cell; Lung cancer
references: Nature. 1998 Mar 19;392(6673):245-52
references: 9521319
references: Annu Rev Immunol. 1991;9:271-96
references: 1910679
references: J Exp Med. 1996 Jan 1;183(1):317-22
references: 8551239
references: Cancer Immunol Immunother. 2003 Mar;52(3):155-61
references: 12649744
references: Vaccine. 2005 Nov 1;23(45):5225-30
references: 16171908
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: J Clin Immunol. 1999 Jan;19(1):12-25
references: 10080101
references: Blood. 2000 Oct 1;96(7):2511-9
references: 11001905
references: Lung Cancer. 2007 Sep;57(3):365-72
references: 17509725
references: J Immunol Methods. 2004 Oct;293(1-2):169-82
references: 15541286
references: N Engl J Med. 2004 Jan 22;350(4):379-92
references: 14736930
references: Nat Immunol. 2000 Sep;1(3):199-205
references: 10973276
references: J Exp Med. 2004 Jun 7;199(11):1503-11
references: 15173207
references: Lung Cancer. 2003 Aug;41 Suppl 1:S103-13
references: 12867069
references: J Transl Med. 2011 Oct 20;9:178
references: 22013914
references: Cancer Immunol Immunother. 2008 Sep;57(9):1335-45
references: 18286287
references: Cytotherapy. 2006;8(2):130-40
references: 16698686
references: Stem Cells. 2004;22(5):725-40
references: 15342937
references: Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809-14
references: 11427731
references: Clin Immunol. 2007 Dec;125(3):257-67
references: 17916447
references: J Urol. 2004 Dec;172(6 Pt 2):2532-8
references: 15538202
references: J Clin Oncol. 2004 Jul 15;22(14):2808-15
references: 15254048